UPDATE 1-Impax broke US antitrust law by delaying generic drug, jury told
Richard Arnold, a lawyer for the retailers, told jurors in his opening statement that Impax in 2008 settled a lawsuit it filed challenging a“weak” patent Medicis Pharmaceutical Corp held for Solodyn by agreeing to delay releasing its a generic version until 2011. In exchange, Impax received $40 million, …